Management of Anemia Among Hemodialysis Patients in Hebron Governorate

Simple item page
dc.contributor.authorAmneh Hawamdeh
dc.contributor.authorRasha Alnatsheh
dc.contributor.authorLina Alhasani
dc.contributor.authorHaneen Nur
dc.contributor.authorAbeer Ghanayem
dc.date.accessioned2023-09-06T10:22:47Z
dc.date.available2023-09-06T10:22:47Z
dc.date.issued2023-05-16
dc.description.abstractBackground: Renal Anemia is a prevalent condition among end-stage of chronic kidney disease (CKD), especially among patients undergoing hemodialysis (HD) due to erythropoietin deficiency. Uncontrolled anemia treatment is a major contributing factor for increased mortality and significant decrease in the Quality of Life (QoL). Medical protocols of renal anemia for end stage CKD patients vary between blood transfusion, erythropoiesis stimulating agents (ESAs) therapy or iron supplements. Palestinian hemodialysis patients receive medical care and treatment in the governmental hospitals. However, the clinical outcomes for HD patients are not clearly assessed.
dc.description.sponsorshipAl-Quds University
dc.identifier.urihttps://dspace.alquds.edu/handle/20.500.12213/8597
dc.language.isoen
dc.publisherAl-Quds University - Deanship of Scientific Research
dc.titleManagement of Anemia Among Hemodialysis Patients in Hebron Governorate
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Management of Anemia Among Hemodialysis Patients in Hebron Governorate.pdf
Size:
154.83 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.61 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medicine & Public Health